# TerrAscend Corp.: Form 10-Q for the period ended Sep 30, 2025

- Company: [TerrAscend Corp.](/companies/tsndf.md) (CIK 1778129)
- Form: 10-Q
- Filed: 2025-11-06
- Accepted by EDGAR: Nov 6, 2025, 07:36 ET
- Period: 2025-09-30
- Accession: 0001193125-25-268099
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1778129/000119312525268099/tsndf-20250930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1778129/000119312525268099/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-07-01 to 2025-09-30 | $65.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2025-01-01 to 2025-09-30 | $194.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2025-07-01 to 2025-09-30 | $31.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2025-01-01 to 2025-09-30 | $92.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2025-07-01 to 2025-09-30 | $33.9m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2025-01-01 to 2025-09-30 | $101.8m | us-gaap:GrossProfit |
| Operating income | 3 months, 2025-07-01 to 2025-09-30 | $11.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2025-01-01 to 2025-09-30 | $34.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2025-07-01 to 2025-09-30 | $7.4m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2025-01-01 to 2025-09-30 | $21.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2025-07-01 to 2025-09-30 | $11.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2025-01-01 to 2025-09-30 | $31.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-07-01 to 2025-09-30 | −$24.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2025-01-01 to 2025-09-30 | −$84.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-07-01 to 2025-09-30 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2025-01-01 to 2025-09-30 | −$0.30 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-07-01 to 2025-09-30 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2025-01-01 to 2025-09-30 | −$0.30 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-07-01 to 2025-09-30 | 306,302,270 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2025-01-01 to 2025-09-30 | 299,550,448 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2025-01-01 to 2025-09-30 | $13.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2025-01-01 to 2025-09-30 | $6.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2025-01-01 to 2025-09-30 | $377.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2025-09-30 | $36.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-09-30 | $119.4m | us-gaap:AssetsCurrent |
| Total assets | at 2025-09-30 | $555.3m | us-gaap:Assets |
| Current liabilities | at 2025-09-30 | $76.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-09-30 | $459.8m | us-gaap:Liabilities |
| Long-term debt | at 2025-09-30 | $230.0m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2025-09-30 | $95.5m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Management's discussion and analysis

As filed, 43,094 characters.

*The following discussion and analysis of financial condition and results of operations of TerrAscend Corp. (the “Issuer”), its subsidiaries, including TerrAscend Growth Corp. (“TerrAscend”) and its subsidiaries (collectively, the “Company”) should be read in conjunction with the Company's unaudited interim condensed consolidated financial statements ("Consolidated Financial Statements") and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial information and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission, (the “SEC”), on March 6, 2025, (the “Annual Report”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q including information with respect to the Company's plans and strategy for its business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth under "Risk Factors" in the Company's Annual Report, its actual results could differ materially from the results described in or implied by the "Cautionary Note Regarding Forward-Looking Statements" contained in this Quarterly Report on Form 10-Q and in the following discussion and analysis.*

*Unless otherwise noted, dollar amounts in this Item 2 are in thousands of U.S. dollars.*

This Management’s Discussion and Analysis (“MD&A”) of the financial condition and results of operations of the Company is for the three and nine months ended September 30, 2025 and 2024 and the accompanying notes for each respective period.

### Overview

The Company is a leading North American cannabis company. The Company has vertically integrated licensed operations in Pennsylvania, New Jersey, Maryland and California and a retail operation in Ohio. In addition, the Company has retail operations in Ontario, Canada with a majority-owned dispensary in Toronto, Ontario, Canada. Notwithstanding the fact that various states in the United States have implemented medical marijuana laws or have otherwise legalized the use of cannabis, the use of cannabis remains illegal under U.S. federal law for any purpose, by way of the Controlled Substances Act of 1970.

The Company operates under one reportable segment, which is the cultivation, production and sale of cannabis products.

The Company owns a portfolio of operating businesses, including:

- TerrAscend New Jersey (“TerrAscend NJ”), a majority owned operation with three dispensaries, and a cultivation/processing facility;
- TerrAscend Maryland (“TerrAscend MD”), a wholly-owned operation with four dispensaries, and a cultivation/processing facility;
- TerrAscend Pennsylvania (“TerrAscend PA”), a wholly-owned operation with six dispensaries, and a cultivation/processing facility;
- TerrAscend California (“TerrAscend CA”), a wholly-owned operation with four dispensaries, and a cultivation facility;
- TerrAscend Ohio ("TerrAscend OH"), a wholly-owned operation with one dispensary; and
- TerrAscend Canada Inc. (“TerrAscend Canada”), a cannabis retailer in Ontario, Canada with a majority-owned dispensary in Toronto, Ontario, Canada ("Cookies Canada").

### Recent Developments

- On August 20, 2025, the Board approved the Share Repurchase Program, which replaces the Company’s Original Program. The Share Repurchase Program authorizes the Company to repurchase up to 10,000,000 Common Shares at any time, or from time to time, from August 22, 2025 until August 21, 2026.
- On July 18, 2025, Keith Stauffer's resignation as the Company’s Chief Financial Officer became effective.
- On July 15, 2025, the Company drew $3,105 of the Uncommitted Term Loan Facility.
- On July 8, 2025, TerrAscend Growth Corp., TerrAscend USA, Inc., TerrAscend NJ LLC, TER Holding MD, Inc., and WDB Holding MD, Inc., including certain of each of their respective subsidiaries, and other borrowers, all of which are entities that are consolidated in the financial statements of the Company (collectively, the “Incremental Amendment Borrowers”), became parties

to the FG Loan as borrowers pursuant to the FG Loan Amendment, which provides for a $79,000 upsize to the existing FG Loan. The FG Loan bears interest at 12.75% per annum and matures on August 1, 2028. The Company drew down in full the $79,000 available under the FG Loan Amendment on July 8, 2025, $68,000 of which was used to retire the Pelorus Term Loan, and certain other indebtedness of the Company, in addition to being used for future growth initiatives. As a result, the outstanding obligation under the Pelorus Term Loan and certain other indebtedness of the Company were repaid in full and subsequently terminated. In addition, the FG Loan Amendment provides for an Uncommitted Term Loan Facility of up to $35,000, of which the Company has drawn $3,105 as of September 30, 2025. Certain funds controlled by the Company’s Executive Chairman, Jason Wild, a related party of the Company, invested approximately $1,600 under the FG Loan Amendment.

### Subsequent Transactions

- The Company received additional indications of interest and preliminary offers from potential buyers. These offers, which were below the previously estimated fair value less cost to sell, provided additional evidence about conditions that existed as of the balance sheet date. Accordingly, management concluded this represented a Type I subsequent event under ASC 855, Subsequent Events, and updated the estimated fair value less cost to sell of the Michigan disposal group as of September 30, 2025. The Company recognized an incremental impairment loss of approximately $6,312 within discontinued operations for the three months ended September 30, 2025
- One of the owned properties included in the Michigan disposal group was subsequently leased to a third party under a lease agreement effective November 1, 2025.

### Components of Results of Operations

The following discussion sets forth certain components of the Company's unaudited condensed consolidated statements of comprehensive loss as well as factors that impact those items.

### Revenue, net

The Company generates revenue from the sale of cannabis products, brands, and services to the U.S. and Canadian markets. Revenues consist of wholesale and retail sales in the legal medical and adult-use market across Canada and in several U.S. states where cannabis has been legalized for medical or adult-use cannabis.

### Cost of sales

Cost of sales primarily consists of expenses related to providing cannabis products and services to the Company's customers, including personnel-related expenses, the depreciation of property and equipment, amortization of acquired intangible assets, certain royalties, and other overhead costs.

### Operating Expenses

#### General and administrative

General and administrative ("G&A") expenses consist primarily of personnel costs related to finance, human resources, legal, certain royalties, and other administrative functions. Additionally, G&A expenses include professional fees to third parties, as well as marketing expenses. Moreover, G&A expenses include share-based compensation on options, restricted stock units and warrants. The Company expects that G&A expenses will increase in absolute dollars as the business grows.

#### Amortization and depreciation

Amortization and depreciation includes the amortization of intangible assets. Amortization is calculated on a straight-line basis over the following terms:

|  |  |
| --- | --- |
| Brand intangibles- indefinite lives | Indefinite useful lives |
| Software | 5 years |
| Licenses | 15-30 years |

Depreciation of property and equipment is calculated on a straight-line basis over the estimated useful life of the asset using the following terms:

|  |  |
| --- | --- |
| Buildings and improvements | 15-30 years |
| Land | Not depreciated |
| Machinery & equipment | 5-15 years |
| Office furniture & production equipment | 3-5 years |
| Right of use assets | Lease term |
| Assets in process | Not depreciated |

### (Gain) loss from revaluation of contingent consideration

As a result of certain acquisitions, the Company recognized contingent consideration liabilities related to price protection provisions. These provisions may require the Company to issue additional Common Shares to the sellers if subsequent prices fall below certain agreed upon prices. These contingent consideration liabilities are remeasured to fair value at the end of each reporting period using the Black-Scholes Model in which a gain or loss is recognized as a result of the revaluation.

### (Gain) loss on fair value of derivative liabilities

The Company issued convertible debt that contains embedded derivative features, which were bifurcated and accounted for separately as derivative instruments. These derivative liabilities are remeasured to fair value at the end of each reporting period using the Black-Scholes Model in which a gain or loss is recognized as a result of the revaluation.

### Loss on extinguishment of debt

Loss on extinguishment of debt represents the Company's debt that was retired prior to its scheduled maturity at a different amount than the book value and the amount paid.

### Finance and other expenses

Finance and other expenses consist primarily of interest and accretion expense on the Company's outstanding debt obligations.

### Unrealized and realized foreign exchange loss

Unrealized and realized foreign exchange loss represents the loss recognized on the remeasurement of USD denominated cash and other assets recorded in the Canadian dollars functional currency at the Company's Canadian operations.

### Provision for income taxes

Provision for income taxes consists of U.S. federal and state income taxes in certain jurisdictions in which the Company conducts business.

### Results of Operations - Three Months Ended September 30, 2025 and September 30, 2024

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

#### Continuing Operations

The following tables represent the Company’s results of operations for the three months ended September 30, 2025 and 2024.

### Revenue, net

*(In thousands)*

|  | For the Three Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| **Revenue, net** | **$65,101** | **$65,161** |
| $ change | $(60) |  |
| % change | 0% |  |

Revenue decreased by $60, from $65,161 for the three months ended September 30, 2024 to $65,101 for the three months ended September 30, 2025. The decrease was primarily due to a $1,527 decline in wholesale revenue, offset by a $1,467 increase in retail revenue.

The $1,527 decrease in wholesale revenue was primarily attributable to increased competition and continued price compression which resulted in lower average selling prices.

The $1,467 increase in retail revenue was primarily attributable to acquisitive growth in 2025.

### Cost of sales

*(In thousands)*

|  | For the Three Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| **Cost of sales** | **$31,176** | **$31,950** |
| $ change | $(774) |  |
| % change | -2% |  |
| Cost of sales as a % of revenue | 48% | 49% |

The decrease of $774, in cost of sales for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024 was mainly due to cultivation and processing efficiencies, partially offset by higher costs associated with acquisitive growth in 2025.

### General and administrative expense

*(In thousands)*

|  | For the Three Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| General and administrative expense | $21,327 | $24,717 |
| $ change | $(3,390) |  |
| % change | -14% |  |

The decrease of $3,390 in general and administrative expense for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024, was primarily due to a reduction in share-based compensation in the current period along with a one-time stock-based compensation charge recognized in the prior-year period related to the modification of stock option terms extending the expiration period from five years to ten years.

### Finance and other expenses

*(In thousands)*

|  | For the Three Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Finance and other expenses | $8,952 | $8,291 |
| $ change | $661 |  |
| % change | 8% |  |

The increase of $661 in finance and other expenses for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024, was primarily due to an increase of interest and accretion related the additional upsize to the existing FG Loan.

### (Gain) loss from revaluation of contingent consideration

*(In thousands)*

|  | For the Three Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| (Gain) loss from revaluation of contingent consideration | $(1,171) | $327 |
| $ change | $(1,498) |  |
| % change | -458% |  |

The gain of $1,171 for the three months ended September 30, 2025, compared to a loss of $327 for the three months ended September 30, 2024, reflects a decrease in the fair value of the contingent consideration liability. This change was primarily driven by the Company’s issuance of Common Shares, which triggered a reduction in the exercise price under the price protection agreement and significantly lowered the likelihood of additional Common Shares being issued.

### Loss (gain) on fair value of derivative liabilities

*(In thousands)*

|  | For the Three Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Loss (gain) on fair value of derivative liabilities | $723 | $(669) |
| $ change | $1,392 |  |
| % change | -208% |  |

The loss on derivative liabilities of $723 for the three months ended September 30, 2025 compared with a gain of $669 for the three months ended September 30, 2024, was primarily driven by an increase in the Company’s stock price during the three months ended September 30, 2025 which resulted in a higher fair value of the derivative instruments and increase in the liability.

### Loss on extinguishment of debt

*(In thousands)*

|  | For the Three Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Loss on extinguishment of debt | $1,432 | $2,096 |
| $ change | $(664) |  |
| % change | -32% |  |

The loss on extinguishment of debt for the three months ended September 30, 2025 and three months ended September 30, 2024 related to the original issuance and subsequent upsizing of the FG Loan, which resulted in the extinguishment of the majority of the Company’s outstanding debt and the write-off of associated deferred financing costs.

### Provision for income taxes

*(In thousands)*

|  | For the Three Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Provision for income taxes | $11,034 | $13,273 |
| $ change | $(2,239) |  |
| % change | -17% |  |

The decrease of $2,239 from $13,273 for the three months ended September 30, 2024 compared to $11,034 for the three months ended September 30, 2025 was primarily driven by higher deductibility of interest offset by accrued interest and penalties.

#### Discontinued Operations

### Discontinued Operations

*(In thousands)*

|  | For the Three Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Loss from discontinued operations, net of tax | $(14,647) | $(5,583) |
| $ change | $(9,064) |  |
| % change | -162% |  |

The loss from discontinued operations, net of tax increased from $5,583 for the three months ended September 30, 2024 to $14,647 for the three months ended September 30, 2025. This was primarily due to a $6,312 impairment charge attributable to subsequent offers from market participants. The remaining increase in loss was primarily due to the termination of certain leases and inventory impairments.

### Results of Operations - Nine Months Ended September 30, 2025 and September 30, 2024

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

#### Continuing Operations

The following tables represent the Company’s results of operations for the nine months ended September 30, 2025 and 2024.

### Revenue, net

*(In thousands)*

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| **Revenue, net** | **$194,410** | **$201,632** |
| $ change | $(7,222) |  |
| % change | -4% |  |

Revenue decreased by $7,222, or 4% from $201,632 for the nine months ended September 30, 2024 to $194,410 for the nine months ended September 30, 2025. The decrease was primarily due to a $7,066 decline in wholesale revenue and a $156 decline in retail revenue.

Wholesale revenue for nine months ended September 30, 2025 and 2024, reflected similar trends to the three month ended periods previously mentioned with continued declines primarily attributable to increased competition and price compression.

Retail revenue for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024, was relatively flat due to a full quarter of acquisitive growth which offset retail revenue declines experienced in prior quarters.

### Cost of sales

*(In thousands)*

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| **Cost of sales** | **$92,568** | **$100,892** |
| $ change | $(8,324) |  |
| % change | -8% |  |
| Cost of sales as a % of revenue | 48% | 50% |

The decrease of $8,324, in cost of sales for the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024 was mainly due to a decrease in sales volume. Cost of sales as a percentage of revenue decreased by 2% due to reduced unit costs and improved cost absorption.

### General and administrative expense

*(In thousands)*

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| General and administrative expense | $63,456 | $68,426 |
| $ change | $(4,970) |  |
| % change | -7% |  |

The decrease of $4,970 in general and administrative expense for the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024 reflected similar trends to the three month ended periods previously mentioned with a reduction in stock-based compensation for the current period along with a one-time stock-based compensation charge recognized in the prior-year period related to the modification of stock option terms extending the expiration period from five years to ten years.

### Finance and other expenses

*(In thousands)*

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Finance and other expenses | $26,034 | $25,094 |
| $ change | $940 |  |
| % change | 4% |  |

Finance and other expenses for nine months ended September 30, 2025 and 2024, reflected similar trends to the three month ended periods previously mentioned with an increase of interest and accretion related the additional upsize to the existing FG Loan.

### Loss from revaluation of contingent consideration

*(In thousands)*

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| (Gain) loss from revaluation of contingent consideration | $(825) | $3,547 |
| $ change | $(4,372) |  |
| % change | -123% |  |

The gain of $825 for the nine months ended September 30, 2025, compared to a loss of $3,547 for the nine months ended September 30, 2024, reflects a decrease in the fair value of the contingent consideration liability. This change was primarily driven by the Company’s issuance of Common Shares, which triggered a reduction in the exercise price under the price protection agreement and significantly lowered the likelihood of additional Common Shares being issued. There was also an expiration of a contingent consideration liability during the nine months ended September 30, 2025.

### Loss (gain) on fair value of derivative liabilities

*(In thousands)*

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Loss (gain) on fair value of derivative liabilities | $347 | $(2,608) |
| $ change | $2,955 |  |
| % change | -113% |  |

Loss (gain) on fair value of derivative liabilities for nine months ended September 30, 2025 and 2024, reflected similar trends to the three month ended periods previously mentioned with primarily driven by an increase in the Company’s stock price which resulted in a higher fair value of the derivative instruments and increase in the liability.

### Loss on extinguishment of debt

*(In thousands)*

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Loss on extinguishment of debt | $1,432 | $2,096 |
| $ change | $(664) |  |
| % change | -32% |  |

The loss on extinguishment of debt for the nine months ended September 30, 2025 and nine months ended September 30, 2024 reflected similar trends to the three month ended periods previously mentioned due to the original issuance and subsequent upsizing of the FG Loan, which resulted in the extinguishment of the majority of the Company’s outstanding debt and the write-off of associated deferred financing costs.

### Provision for income taxes

*(In thousands)*

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Provision for income taxes | $31,139 | $30,052 |
| $ change | $1,087 |  |
| % change | 4% |  |

The increase of $1,087 from $30,052 for the nine months ended September 30, 2024 compared to $31,139 for the nine months ended September 30, 2025 was primarily driven by accrued interest and penalties.

#### Discontinued Operations

### Discontinued Operations

*(In thousands)*

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Loss from discontinued operations, net of tax | $(60,952) | $(11,191) |
| $ change | $(49,761) |  |
| % change | 445% |  |

The change in loss from discontinued operations, net of tax from $11,191 for the nine months ended September 30, 2024 as compared to the loss from discontinued operations, net of tax of $60,952 was primarily driven by a $41,271 impairment charge that was recognized in the nine months ended September 30, 2025 attributable to the Company’s expedited sales strategy, constructions in process that will no longer be completed, and the continued increase of competition in the Michigan market and continued market saturation and price compression in Michigan which negatively impacted gross margins. The loss was also impacted by the termination of certain leases and inventory write-offs.

### Liquidity and Capital Resources

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

|  | September 30, 2025 | December 31, 2024 |
| --- | ---: | ---: |
| Cash and cash equivalents | $36,516 | $26,381 |
| Restricted Cash | 110 | 606 |
| Current assets | 119,365 | 176,888 |
| Non-current assets | 435,895 | 430,343 |
| Current liabilities | 76,307 | 91,049 |
| Non-current liabilities | 383,472 | 339,366 |
| Working capital | 43,058 | 85,839 |
| Total shareholders' equity | $95,481 | $176,816 |

The calculation of working capital provides additional information and is not defined under accounting principles generally accepted in the United States of America ("GAAP"). The Company defines working capital as current assets less current liabilities. This measure should not be considered in isolation or as a substitute for any standardized measure under GAAP.

Since its inception, the Company's primary sources of capital have been through the issuance of equity securities or debt facilities, and the Company has received aggregate net proceeds from such transactions totaling $861,332 as of September 30, 2025.

The Company expects to fund any additional future requirements through the following sources of capital:

- cash from ongoing operations.
- market offerings.
- additional debt from additional creditors.
- sale of real property.
- sale leaseback transactions.
- exercise of options and warrants.

The Company had $230,048 in principal amounts of loans payable at September 30, 2025. Of this amount, $716 are due within the next twelve months.

The Company entered into leases for certain premises and offices for which it owes monthly lease payments. The Company had $62,651 in undiscounted lease obligations. Of this amount, $4,633 are due in the next twelve months.

The Company's undiscounted contingent consideration payable was $179 at September 30, 2025, which is due in the next twelve months. The contingent consideration payable relates to the Company's acquisition of the remaining 50.1% equity in both State Flower and three Apothecarium dispensaries in California. The contingent consideration is based upon the price protection of Common Shares issued under the terms of the applicable acquisition agreement. The contingent consideration is measured at fair value using the Black-Scholes Model and revalued at the end of each reporting period.

At September 30, 2025, the Company had accounts payable and accrued liabilities of $35,993 and corporate income taxes payable of $8,338.

The Company does not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the Company's results of operations or financial condition, including and without limitation, such consideration as liquidity and capital resources.

The Company intends to meet its capital commitments through any or all of the sources of capital noted above. The Company's objective with respect to its capital management is to ensure it has sufficient cash resources to maintain its ongoing operations and finance future obligations.

### Debt Facilities

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

*(In thousands)*

|  | Principal Paid during the Nine Months Ended September 30, 2025 | Principal Outstanding as of September 30, 2025 |
| --- | ---: | ---: |
| FocusGrowth Term Loan | $— | $222,105 |
| Pelorus Term Loan | 45,478 | — |
| Maryland Acquisition Loans | 15,207 | 2,931 |
| FG Bridge Loan | 5,208 | — |
| Ratio Promissory Note | — | 3,980 |
| Other Loans | 5 | 1,032 |
| Total | **$65,898** | **$230,048** |

### FocusGrowth Term Loan

On August 1, 2024, the Issuer and TerrAscend USA, Inc., as guarantors, and each of WDB Holding CA, Inc., WDB Holding PA, Inc., Moose Curve Holdings, LLC, Hempaid, LLC and, pursuant to a joinder agreement dated September 30, 2024, WDB Holding MI, Inc., including certain of each of their respective subsidiaries, as borrowers, and FG Agency Lending LLC, as the Administrative Agent entered into a Loan Agreement for a four-year, $140,000 senior-secured term loan Net proceeds of the FG Loan were received in an amount equal to 95% of the $140,000.

The FG Loan bears interest at 12.75% per annum and matures on August 1, 2028. The FG Loan is guaranteed by the Issuer and TerrAscend USA, Inc. and is secured by substantially all of the assets of the Borrowers. Depending on the timing of repayment, an exit fee of between 2.0% and 4.0% of the outstanding principal balance of the FG Loan will be due upon either prepayment, in part or in full, of the FG Loan or the FG Loan Maturity Date.

The FG Loan includes negative covenants that are usual for facilities and transactions of this type. The FG Loan contains covenants that limit the borrowers’ ability to, among other things: (i) incur additional indebtedness or guarantee indebtedness; (ii) create liens; (iii) pay dividends; (iv) make investments; (v) enter into transactions with affiliates; and (vi) consolidate, merge, sell or otherwise dispose of all or substantially all of their respective assets. The FG Loan also includes a minimum liquidity covenant with respect to the borrowers. If an event of default occurs and is not cured within an applicable grace period or waived, the principal amount, any accrued interest and any other obligations outstanding under the FG Loan may become immediately due and payable.

On July 8, 2025, TerrAscend Growth Corp., TerrAscend USA, Inc., TerrAscend NJ LLC, TER Holding MD, Inc., and WDB Holding MD, Inc., including certain of each of their respective subsidiaries, and other borrowers, all of which are entities that are consolidated in the financial statements of the Company (collectively, the “Incremental Amendment Borrowers”), became parties to the FG Loan as borrowers pursuant to the FG Loan Amendment, which provided for an additional $79,000 upsize to the existing FG Loan. The Company drew down in full the $79,000 available under the FG Loan Amendment on July 8, 2025, $68,000 of which was used to retire the Pelorus Term Loan, and certain other indebtedness of the Company, in addition to being used for future growth initiatives.

On July 15, 2025, the Company drew $3,105 of the Uncommitted Term Loan Facility.

As of September 30, 2025, there was an outstanding principal amount of $222,105 under the FG Loan.

### Maryland Acquisition Loans

In connection with the Maryland Acquisitions, the Company entered into a series of promissory notes with an aggregate principal amount of $20,625.

On July 8, 2025, as described above, the Company entered into the FG Loan Amendment, of which, a portion of the proceeds was used to retire a series of Maryland promissory notes and pay an outstanding principal amount of $13,077. Due to the early retirement of the certain Maryland promissory notes, the Company recognized a loss on extinguishment of debt of $240 on the Consolidated Statements of Operations and Comprehensive Loss.

As of September 30, 2025, there was an outstanding principal amount of $2,931 under the promissory notes related to the Maryland Acquisitions Loans associated with Blue Ridge, which bears interest at 7.0% with a maturity date of June 30, 2027.

### Ratio Promissory Note

As a part of the Ratio Acquisition, the Company entered into a promissory note for $3,980 bearing 6% interest with a two-year maturity.

As of September 30, 2025, there was an outstanding principal amount of $3,980 under the Ratio Promissory Note.

### Class A Shares of TerrAscend Growth

In connection with the listing of the Common Shares on the TSX, the Company reorganized its ownership structure to segregate the Company’s Canadian retail operations from TerrAscend's cultivation and manufacturing operations in the United States. As a result, TerrAscend issued $1,000 of Class A Shares with a 20% guaranteed annual dividend to the Investor pursuant to the terms of the Subscription Agreement. Pursuant to the terms of the Subscription Agreement, TerrAscend holds a call right to repurchase all of the Class A Shares issued to the Investor for an amount equal to the sum of: (a) the Repurchase/Put Price (as defined in the Subscription Agreement); plus (b) the amount equal to 40% of the subscription amount less the aggregate dividends paid to the Investor as of the date of the exercise of the repurchase right. In addition, the Investor holds a put right that is exercisable at any time after four months’ advanced written notice following June 28, 2028 to put all (and only all) of the Class A Shares owned by the Investor to TerrAscend at the Repurchase/Put Price, payable in cash or shares. The instrument is considered as a debt for accounting purposes due to the economic characteristics and risks. As of September 30, 2025, there was an outstanding principal amount of $1,000.

### Share Repurchases

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

On August 20, 2025, the Board approved the Share Repurchase Program, which replaced the Original Program. The Share Repurchase Program authorizes the Company to repurchase up to 10,000,000 Common Shares of the Company at any time, or from time to time, from August 22, 2025 until August 21, 2026. The Share Repurchase Program authorizes the Company to repurchase up to 60,255 Common Shares daily, which represents 25% of the Company’s average daily trading volume on the TSX of 241,023 Common Shares. Any repurchases under the program may be made by means of open market transactions, negotiated block transactions, or otherwise, including pursuant to a repurchase plan administered in accordance with Rules 10b5-1 and 10b-18 under the Securities Exchange Act of 1934, as amended. The size and timing of any repurchases will depend on price, market and business conditions, and other factors.

During the third quarter of 2025, the Company did not repurchase common shares under the Share Repurchase Program. As of September 30, 2025, the Company had a total of 10,000,000 Common Shares remaining that can be authorized for repurchase.

### Cash Flows

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

### Cash flows provided by operating activities

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $13,514 | $28,202 |

The decrease of $14,688 in net cash provided by operating activities for the nine months ended September 30, 2025 as compared to nine months ended September 30, 2024 was primarily driven by an increase in working capital including a reduction of accounts payable and an increase in income taxes paid.

### Cash flows used in investing activities

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Net cash used in investing activities | $(13,464) | $(6,269) |

The increase of $7,195 in net cash used in investing activities for the nine months ended September 30, 2025 as nine months ended September 30, 2024 was primarily driven by the cash consideration paid of $5,261 for the Ratio Cannabis acquisition in the second quarter of 2025. The increase was also attributable to ongoing capital expenditure projects focused on expansion and high product quality.

### Cash flows provided by (used in) financing activities

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Net cash provided by (used in) financing activities | $10,004 | $(20,316) |

The change of $30,320 in net cash provided by financing activities for the nine months ended September 30, 2025 as compared to the net cash used in financing activities for the nine months ended September 30, 2024 was primarily driven by net loan proceeds of $12,813 received slightly offset by distributions to non-controlling interests of $2,046 in the current-year period, while prior-year period included net loan principal payments of $14,889 and distributions to non-controlling interests of $4,433.

### Reconciliation of Non-GAAP Measures

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

In addition to reporting the financial results in accordance with GAAP, the Company reports certain financial results that differ from what is reported under GAAP. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company believes that certain investors and analysts use these measures to measure a company’s ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry, and the Company calculates: (i) Free cash flow from net cash provided by operating activities from continuing operations less capital expenditures for property and equipment which management believes is an important measurement of the Company's ability to generate additional cash from its business operations, and (ii) EBITDA from continuing operations and Adjusted EBITDA from continuing operations as net loss, adjusted to exclude provision for income taxes, finance expenses, depreciation and amortization, share-based compensation, unrealized and realized (gain) loss on investments, (gain) loss from revaluation of contingent consideration, unrealized and realized foreign exchange (gain) loss, gain on fair value of derivative liabilities, impairment of property and equipment and right of use assets, gain on lease terminations, and certain other items, which management believes is not reflective of the ongoing operations and performance of the Company. Such information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

The Company believes Adjusted EBITDA from continuing operations is a useful performance measure to assess the performance of the Company as it provides more meaningful ongoing operating results by excluding the effects of expenses that are not reflective of the Company’s underlying business performance and other one-time or non-recurring expenses. The table below reconciles net loss to EBITDA from continuing operations and Adjusted EBITDA from continuing operations for the three and nine months ended September 30, 2025 and 2024:

*(In thousands)*

|  | Notes | For the Three Months Ended September 30, 2025 | September 30, 2024 | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | --- | ---: | ---: | ---: | ---: |
| **Net loss** |  | **$(24,554)** | **$(21,419)** | **$(84,929)** | **$(42,508)** |
| Loss (income) from discontinued operations |  | 14,647 | 5,583 | 60,952 | 11,191 |
| Loss from continuing operations |  | (9,907) | (15,836) | (23,977) | (31,317) |
| Add (deduct) the impact of: |  |  |  |  |  |
| Provision for income taxes |  | 11,034 | 13,273 | 31,139 | 30,052 |
| Finance expenses |  | 9,243 | 8,514 | 26,626 | 25,654 |
| Amortization and depreciation |  | 3,934 | 3,781 | 11,663 | 11,358 |
| **EBITDA from continuing operations** | (a) | **14,304** | **9,732** | **45,451** | **35,747** |
| Add (deduct) the impact of: |  |  |  |  |  |
| Share-based compensation | (b) | 1,366 | 4,275 | 3,659 | 7,720 |
| Loss on extinguishment of debt | (c) | 1,432 | 2,096 | 1,432 | 2,096 |
| Gain on fair value of derivative liabilities | (d) | 723 | (669) | 347 | (2,608) |
| Unrealized and realized foreign exchange (gain) loss | (e) | 77 | (214) | (530) | 175 |
| Unrealized and realized (gain) loss on investments | (f) | 1 | (14) | 736 | 213 |
| (Gain) Loss from revaluation of contingent consideration | (g) | (1,171) | 327 | (825) | 3,547 |
| Impairment of property and equipment and right of use assets | (h) | — | — | — | 2,438 |
| Gain on lease termination | (i) | — | — | — | (1,169) |
| Other one-time items | (j) | 266 | 1,351 | 890 | 4,015 |
| **Adjusted EBITDA from continuing operations** |  | **$16,998** | **$16,884** | **$51,160** | **$52,174** |

a) EBITDA from continuing operations is a non-GAAP measure and is calculated from net loss.

b) Represents non-cash share-based compensation expense.

c) Represents the loss taken to extinguish certain debt.

d) Represents the gain on fair value of conversion options.

e) Represents the remeasurement of USD denominated cash and other assets recorded in CAD functional currency.

f) Represents unrealized and realized loss on fair value changes investments.

g) Represents the revaluation of the Company's contingent consideration liabilities.

h) Represents impairment charges taken on the Company's property and equipment and right of use assets.

i) Represents the gain taken as a result on lease termination.

j) Includes one-time fees incurred primarily in connection with the Company's acquisitions and other costs considered one-time in nature, such as expenses related to professional, consulting, legal, and accounting fees. These fees are not indicative of the Company's ongoing costs.

Adjusted EBITDA from continuing operations was relatively flat for the three and nine months ended September 30, 2025 as compared to three and nine months ended September 30, 2024.

The table below reconciles net cash provided by operating activities from continuing operations to free cash flow for the nine months ended September 30, 2025 and 2024:

*(In thousands)*

|  | For the Nine Months Ended September 30, 2025 | September 30, 2024 |
| --- | ---: | ---: |
| Net cash provided by operating activities - continuing operations | **$25,599** | **$39,424** |
| Capital expenditures for property and equipment | (6,898) | (4,111) |
| **Free Cash Flow** | **$18,701** | **$35,313** |

### Critical Accounting Estimates and Policies

The Consolidated Financial Statements have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. The Company bases its estimates on historical experience and assumptions on an ongoing basis. Actual results may differ from these estimates. To the extent that there are material differences between these estimates and actual results, the Company's future financial statements will be affected.

There have been no significant changes to the critical accounting estimates from the information provided in Item 7, "*Management's Discussion and Analysis of Financial Condition and Results of Operations*", as contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

### Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company's Consolidated Financial Statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

The Company will remain an emerging growth company until the earlier to occur of: (i) December 31, 2027 (a) in which the Company has total annual gross revenue of $1,235,000 or more, or (b) in which the Company is deemed to be a large accelerated filer, which means the market value of the Company's Common Shares that are held by non-affiliates exceeds $700,000 as of the last business day of the Company’s most recent second fiscal quarter; and (ii) the date on which the Company has issued more than $1,000,000 in non-convertible debt during the prior three-year period.

## Market risk

As filed, 205 characters.

There have been no material changes in the Company's primary risk exposures or management of market risks from those disclosed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

## Controls and procedures

As filed, 2,128 characters.

### Evaluation of Disclosure Controls and Procedures

The Company's management, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that, as of September 30,

2025, the Company's disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2025, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

### Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the Company's disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

## Risk factors

As filed, 732 characters.

Investing in the Company's Common Shares involves a high degree of risk. Please refer to Part I, Item 1A, “Risk Factors” in the Company's Annual Report for a description of the material risks and uncertainties to which the Company’s business, financial condition and results of operations are subject. The Company may disclose changes to risk factors or disclose additional factors from time to time in its future filings with the SEC. Additional risks and uncertainties not presently known to the Company or that the Company currently deems immaterial may impair its business operations. There have been no material changes to the risk factors previously disclosed in Part I, Item 1A, “Risk Factors” in the Company's Annual Report.

Filed Nov 6, 2025.
Source: SEC EDGAR, the filing index for accession 0001193125-25-268099. Last ingested by Listed: Nov 5, 2026, 17:55 ET. No prices; not investment advice.
